Soligenix announced that its investigational therapy SGX945, a dusquetide‑based innate defense regulator, has received the UK Medicines and Healthcare Products Regulatory Agency’s (MHRA) Promising Innovative Medicine (PIM) designation for the treatment of Behçet’s disease.
The PIM designation is the first step toward inclusion in the UK Early Access to Medicines Scheme (EAMS), which allows severely ill patients to receive experimental treatments earlier than through the standard approval pathway. The designation signals that the MHRA believes SGX945 offers a major advantage over existing therapies for a rare disease with a high unmet medical need.
Phase 2 clinical data underpin the designation: in a study of Behçet’s disease, 7 of 8 patients experienced rapid ulcer healing that persisted after treatment cessation, and the safety profile was favorable compared with the approved drug apremilast, which is associated with gastrointestinal and neurological side effects.
In addition to the UK milestone, the European Medicines Agency’s Committee for Orphan Medicinal Products issued a positive recommendation for orphan drug designation for dusquetide for Behçet’s disease on February 26 2026, adding regulatory momentum in the EU market.
Soligenix’s market capitalization is $12.1 million and the company has not reported revenue growth over the past three years, with negative earnings‑per‑share, operating, and net margins. The PIM designation therefore represents a significant positive development that could improve the company’s commercial prospects, though it remains financially challenged.
CEO Christopher J. Schaber said, “We are excited that the MHRA agrees that dusquetide meets the specified criteria for PIM designation based on the Phase 2 clinical data in Behçet’s disease, in conjunction with the consistency that has been observed in previous clinical studies in oral mucositis.” He added, “We look forward to working with the MHRA to advance the program and leverage the potential benefits of the EAMS scheme to make this important product available to patients and physicians facing the challenges of Behçet’s disease.”
The PIM designation positions SGX945 for earlier patient access in the UK and may accelerate its commercial trajectory, but Soligenix’s ongoing financial challenges underscore the need for continued investment and successful regulatory progress to realize market potential.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.